Merrimack Pharmaceuticals reports Q2 results
- BySeeking Alpha-
Merrimack Pharmaceuticals (MACK): FY GAAP EPS of -$0.22.Cash and cash equivalents and investments of $14.0 million, compared to $16.6 million as of December 31, 2019.Press Release
Gainers: [[CASA]] +25.2%. [[TA]] +8.2%. [[NVAX]] +6.9%. [[AXTI]] +5.5%. [[MACK]] +5%.Losers: [[RXT]] -11.8%. [[CNDT]] -8.3%. [[EHTH]] -6.3%. [[APPN]] -5.4%. [[CENX]] -4%.
Shares of Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) are recovering this year after a massive fall and a sharp decline in 2018. The biotech stock has jumped 48.7% this year so...
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) incurred a loss of 92 cents per share for the third quarter of 2018, significantly wider than the Zacks Consensus Estimate of a loss...
It is usually believed that that drug biotech sector is a safe haven for investors as the sector enjoys strong fundamentals. Large Cap Pharma/Biomed/Genetics Sector vs. S&P 500...
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is entitled to receive contingent milestone payments related to its sale of ONIVYDE to Ipsen S.A. ONIVYDE is approved by the Unites States Food and Drug Administration (FDA) in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. The Company does not have any ongoing research or development activities and is seeking potential acquirers for its remaining preclinical and clinical assets.